Skip to content
Aminoscope
← Research
Peptides

CJC-1295 side effects: what's measured, what's inferred, and the DAC concern

Injection-site reactions and flushing are the commonly reported effects; fluid retention, carpal-tunnel-like tingling, and glucose changes are inferred from GH excess. The DAC's real signature is a raised, non-pulsatile GH trough.

Priya Anand6 min read
Pulsatile natural GH versus the raised, sustained baseline of CJC-1295 DACPlasma GHtime →natural GH — pulsatileCJC-1295 DAC — raised troughPULSATILE VS SUSTAINED GH — THE DAC CONCERN
Need a closer look?Enlarge illustration

CJC-1295’s side effects are poorly measured. Its only controlled human trials found no serious reactions, but the FDA lists serious adverse events reported with it, including a raised heart rate and a systemic vasodilatory (flushing, blood-pressure) reaction. Fluid retention, wrist tingling and higher blood sugar are expected from raised growth hormone. It is not FDA-approved.

CJC-1295 is a synthetic, long-acting analog of growth-hormone-releasing hormone (GHRH), usually sold in the “DAC” form that binds albumin and stretches its half-life to days. It is not an FDA-approved drug, and the honest problem with cataloguing its side effects is that almost nobody has studied them properly. The ipamorelin & CJC-1295 evidence review covers what researchers have measured for efficacy. This page separates the limited human safety findings from effects inferred from the biology of a raised GH/IGF-1 axis.

What human data actually exist

The controlled human record is essentially one small study. Teichman and colleagues gave CJC-1295 to healthy adults in ascending-dose, placebo-controlled trials of 28 and 49 days and reported that a single injection raised mean plasma GH two- to tenfold for six days or more and IGF-1 1.5- to threefold for nine to eleven days, on an estimated half-life of 5.8 to 8.1 days — with no serious adverse reactions and a drug that was “relatively well tolerated.”[1] That is reassuring as far as it goes — but it was a pharmacokinetic and pharmacodynamic study in a few dozen people, not a trial powered or designed to detect harm, and it says nothing about months or years of use. So the correct starting posture is not “it looks safe” but “it has barely been studied.”

The FDA’s own compounding safety list adds a harder note. It says compounded CJC-1295 may pose a risk of immune reactions and impurity problems, and that the agency “has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction,” with “available clinical data” described as limited. CJC-1295 sits on the FDA’s “nominated but withdrawn” list, so as of October 2026 it is not cleared for pharmacy compounding.[5]

The commonly reported, milder effects

The effects most often described with GHRH-class peptides are local and vascular: injection-site reactions (redness, itching, a small welt), transient flushing, and headache. These are consistent with the pharmacology of a subcutaneously injected vasoactive peptide, and they map onto what is documented for approved GHRH analogs. Because CJC-1295 itself has not been characterized for these specifically beyond the “well tolerated” summary above, the better-described sibling profile lives on the sermorelin side-effects page — sermorelin being an approved, shorter-acting GHRH analog whose adverse-event profile is far better documented.

Water retention, tingling, and glucose: the GH-excess signature

The effects people worry about most are not unique to CJC-1295 — they are the classic consequences of pushing the GH/IGF-1 axis, and they are best characterized in states of chronic GH excess. Sustained GH promotes sodium and fluid retention, producing soft-tissue swelling and edema; the same soft-tissue expansion around the wrist is a recognized cause of carpal tunnel syndrome, which is the mechanism behind the tingling and numbness research users describe.[4] And GH is a counter-regulatory hormone: sustained elevation antagonizes insulin, raising the risk of insulin resistance and impaired glucose tolerance.[3] None of these has been measured in CJC-1295 users specifically — the point is that the drug’s entire mechanism is to raise the exact hormones that, in excess, drive these effects.

The DAC-specific concern: a raised trough, not a pulse

Here is the concern that is genuinely specific to the long-acting DAC form. Natural GH is secreted in sharp pulses that fall back to a near-zero baseline between peaks, and that pulsatile pattern is thought to matter for the hormone’s normal physiology. When Ionescu and Frohman gave a single CJC-1295 injection (60 or 90 micrograms per kilogram) to healthy men aged 20 to 40 and sampled GH overnight a week later, the pulses were preserved — their frequency and magnitude were unchanged — but basal (trough) GH rose roughly 7.5-fold (P < 0.0001). That raised interpulse floor contributed to a 46% rise in mean GH, and IGF-1 rose 45%.[2] In other words, the DAC version does not so much amplify the peaks as lift the valleys, shifting a naturally pulsatile signal toward a more continuous elevation.[1] Whether that chronically raised baseline carries the same long-term risk as GH excess is exactly the question no study of this peptide has answered.

Swipe to see all columns

CJC-1295's reported effects, sorted by how much is actually known. Only the pharmacodynamics are human-measured; the harms are inferred from GH-excess biology.
Reported effectEvidence status for CJC-1295Basis
Injection-site reactions, flushing, headacheNot specifically characterized; overall 'well tolerated' in one small studyGHRH-class pharmacology; Teichman
Increased heart rate, systemic vasodilatory reactionSerious adverse events the FDA says it has identifiedFDA compounding safety list
Fluid retention / edemaNot measured in users; mechanistically expectedGH-excess physiology (Melmed)
Tingling / numbness (carpal-tunnel-like)Not measured in users; mechanistically expectedSoft-tissue swelling in GH excess (Melmed)
Impaired glucose tolerance / insulin resistanceNot measured in users; mechanistically expectedGH antagonizes insulin (Melmed)
Raised trough (non-pulsatile) GH from the DACDemonstrated in humansIonescu & Frohman; Teichman
CJC-1295's reported effects, sorted by how much is actually known. Only the pharmacodynamics are human-measured; the harms are inferred from GH-excess biology. PMIDs 16352683, 17018654, 19884662, 17167139; FDA compounding safety list (content current April 22, 2026)

The supply problem sits on top of all of this

Everything above assumes the vial contains pure CJC-1295 at the stated amount. It usually cannot be assumed. These peptides are sold almost entirely as “research-use-only”products made outside pharmaceutical manufacturing standards, which means the purity, sterility, actual dose, and even the identity of the contents are unverified. Contaminants, endotoxin, incorrect peptides, and inconsistent concentration are all realistic — and those risks are entirely separate from, and additional to, the peptide’s own pharmacology. A clean safety story about the molecule would not rescue a contaminated vial. This is why no discussion of dose belongs here; if you want to see how that same caution frames the numbers, the CJC-1295 & ipamorelin dosage page treats it the same way.

How this differs from ipamorelin

CJC-1295 and ipamorelin are frequently stacked but act at different points. Ipamorelin is a selective ghrelin-mimetic secretagogue that triggers a short GH pulse; CJC-1295 is the GHRH analog whose DAC form gives the sustained, trough-raising exposure described above. That difference matters for side effects: the DAC’s prolonged, non-pulsatile elevation is the concern unique to CJC-1295, whereas ipamorelin’s effects have their own profile — covered on the ipamorelin side-effects page.

The honest bottom line

CJC-1295’s side-effect profile is mostly a set of well-founded predictions, not a measured record. One small human study found it relatively well tolerated with no serious reactions,[1] though the FDA notes serious adverse events reported with it, including increased heart rate;[5] the fluid retention, carpal-tunnel-like tingling, and glucose effects are inferred from what sustained GH/IGF-1 excess reliably does;[3][4] and the DAC form’s signature move is to raise the between-pulse GH floor rather than preserve the natural low trough.[2] Layer on an unregulated supply chain of unknown purity, and the appropriate stance is caution and a clinician — not a stack assembled from a forum. Sermorelin, a GHRH analog that pharmacies can still compound, is the prescription route most telehealth services offer; the PlexusDx review shows it at $179 a month, or $129 on a six-month plan.

Reviewed against primary sources by the Aminoscope desk

Sources

  1. [1] Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. PMID 16352683
  2. [2] Ionescu M, Frohman LA. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. PMID 17018654
  3. [3] Melmed S. (2009). Acromegaly pathogenesis and treatment. J Clin Invest. PMID 19884662
  4. [4] Melmed S. (2006). Medical progress: Acromegaly. N Engl J Med. PMID 17167139
  5. [5] U.S. Food and Drug Administration. (2026). Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026). FDA. Source

Where to get it

Where to get peptide therapy

Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm availability before ordering.

Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.

Provider reviews we publish: EdgeRxPeptiAurenRxthe edit.VyvronLighter You

Related tool

Peptide evidence matrix

See every peptide graded by how strong the human evidence actually is — filter by evidence tier, with a primary source on each grade.

More in Peptides